| 01/23 | Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Comb.. | CI |
| 01/20 | Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities | PU |
| 2022 | Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders | PU |
| 2022 | Biotech Group TMA Pharma's CFO to Leave by 2022-end | MT |
| 2022 | Tme Pharma N : announces the resignation of its Chief Financial Officer Bryan Jennings | PU |
| 2022 | TME Pharma N.V. Announces Executive Changes | CI |
| 2022 | TME Pharma N.V. Announces the Resignation of Bryan Jennings as Chief Financial Officer | CI |
| 2022 | Tme Pharma N : The presentation | PU |
| 2022 | TME Pharma N.V. - POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRA.. | AQ |
| 2022 | TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in .. | CI |
| 2022 | Tme pharma announces publication of abstract disclosing positive interim results from b.. | AQ |
| 2022 | Tme Pharma N : to host key opinion leader webinar | PU |
| 2022 | Tme Pharma N : announces publication of abstract disclosing positive interim results from .. | PU |
| 2022 | TME Pharma Announces Publication of Abstract Disclosing Positive Interim Results from B.. | CI |
| 2022 | TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
| 2022 | Tme Pharma N : Inside Information / News release on accounts, results | PU |
| 2022 | Tme Pharma N : 2022, Half-Year Financial Report as of 30 June 2022 | PU |
| 2022 | Tme pharma announces upcoming presentation at the society for neuro-oncology annual mee.. | AQ |
| 2022 | TME Pharma - SAFETY CONFIRMED OF NOX-A12 AND PEMBROLIZUMAB COMBINATION IN GLORIA PHASE .. | AQ |
| 2022 | Data Safety Monitoring Board Validates Safety Data for TME Pharma's Brain Cancer Therap.. | MT |
| 2022 | TME Pharma N.V. Announces Data Safety Monitoring Board Validated Safety Data from the I.. | CI |
| 2022 | TME Pharma Treats First Brain Cancer Patient In Phase 1/2 Clinical Study | MT |
| 2022 | TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-.. | CI |
| 2022 | Noxxon Pharma N : Inside Information / Other news releases | PU |
| 2022 | French Drugmaker Noxxon Changes Name to TME Pharma | MT |
| 2022 | Noxxon pharma announces changes to its supervisory board | AQ |
| 2022 | Noxxon pharma - half-yearly report on the liquidity contract with invest securities | AQ |
| 2022 | NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, .. | CI |
| 2022 | Noxxon Pharma N : Bryan Jennings | PU |
| 2022 | Noxxon Pharma N : 1 July 2022 | PU |
| 2022 | Noxxon Pharma N : AFM notification form MAR 19 – managers transactions | PU |
| 2022 | Noxxon provides results of its 2022 annual general meeting of shareholders | AQ |
| 2022 | Noxxon Pharma N : Download transcript | PU |
| 2022 | NOXXON Pharma N.V. has Changed its Name to TME Pharma N.V | CI |
| 2022 | Noxxon announces corporate action to start the parity period | AQ |
| 2022 | NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observe.. | CI |
| 2022 | Noxxon enters into collaboration with us national cancer institute to characterize effe.. | AQ |
| 2022 | NOXXON Pharma N.V. Enters into Amaterial Transfer Agreement with the U.S. National Canc.. | CI |
| 2022 | Noxxon Pharma N : KOL Event Presentation NOX-A12 Phase 1/2 GLORIA trial in glioblastoma | PU |
| 2022 | Noxxon presents full top-line results from nox-a12 phase 1/2 gloria trial in glioblasto.. | AQ |
| 2022 | Noxxon to host key opinion leader webinar on gloria study top-line results of nox-a12 &.. | AQ |
| 2022 | NOXXON announces convocation of the 2022 annual general meeting of shareholders | AQ |
| 2022 | NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASC.. | CI |
| 2022 | Noxxon amends equity-linked facility with atlas | AQ |
| 2022 | Noxxon Obtains Additional $1 Million in Remaining Tranches of Equity-linked Facility | MT |
| 2022 | Noxxon announces results of the extraordinary general meeting of shareholders | AQ |
| 2022 | Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments | CI |
| 2022 | TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 2022 | Noxxon announces eur2.375 million financing under agreement with atlas | AQ |
| 2022 | NOXXON Pharma N.V. Auditor Raises 'Going Concern' Doubt | CI |
| 2022 | Top-line results from noxxon's nox-a12 phase 1/2 gloria trial in brain cancer to be pre.. | AQ |
| 2022 | Noxxon Pharma N : Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain ca.. | PU |
| 2022 | Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to B.. | CI |
| 2022 | NOXXON Announces Top-Line Data of Phase 1/2 GLORIA Study With NOX-A12 in Partially Rese.. | CI |
| 2022 | Noxxon announces eur2.375 million financing under agreement with atlas | AQ |
| 2022 | Cancer-Focused Biotech Noxxon Secures Additional $2.7 Million Financing | MT |
| 2022 | Noxxon - half-yearly report on the liquidity contract with invest securities | AQ |
| 2022 | Noxxon provides progress update on the expansion arms of the phase 1/2 gloria trial wit.. | AQ |
| 2022 | NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial Wit.. | CI |
| 2022 | Noxxon provides update on evaluation of nox-a12 in non- oncology indication by a leadin.. | AQ |
| 2022 | NOXXON Pharma N.V. Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication .. | CI |
| 2022 | NOXXON Pharma N.V. announced that it expects to receive €17 million in funding | CI |
| 2021 | Noxxon Gets Additional $19 Million Funding From Atlas Special Opportunities | MT |
| 2021 | Noxxon Pharma N : secures Euro 17 million expansion of equity-linked facility with Atlas t.. | PU |
| 2021 | NOXXON Pharma N.V. Announces Appointment of Bryan Jennings as Additional Statutory Dire.. | CI |
| 2021 | Noxxon Pharma N : announces results of the extraordinary general meeting of shareholders | PU |
| 2021 | Noxxon Pharma N : to participate in banking and investor conferences in January and Februa.. | PU |
| 2021 | Global markets live: Intel, Tesla, Facebook, ABB, SGS... | |
| 2021 | NOXXON Pharma N.V. Announces Enrolment of First Patient in the Expansion of the NOX-A12.. | CI |
| 2021 | NOXXON Pharma N.V. Presents New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in.. | CI |
| 2021 | Noxxon : New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presente.. | PU |
| 2021 | Noxxon Pharma N : Presentation by Dr. Frank Giordano at the Society for Neuro-Oncology (SN.. | PU |
| 2021 | Noxxon to host key opinion leader webinar on nox-a12 and radiotherapy combination, a di.. | AQ |
| 2021 | Noxxon To Host Key Opinion Leader We : a differentiated and promising new approach to trea.. | PU |
| 2021 | Noxxon Pharma N : announces convocation of an Extraordinary General Meeting of shareholder.. | PU |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
